Published in Sci Rep on July 29, 2016
Radiation dose enhancement in skin therapy with nanoparticle addition: A Monte Carlo study on kilovoltage photon and megavoltage electron beams. World J Radiol (2017) 0.75
Extracellular Matrix, a Hard Player in Angiogenesis. Int J Mol Sci (2016) 0.75
Gold nanoparticles attenuate metastasis by tumor vasculature normalization and epithelial-mesenchymal transition inhibition. Int J Nanomedicine (2017) 0.75
Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer (2017) 0.75
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Angiogenesis in life, disease and medicine. Nature (2005) 15.36
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol (2006) 7.19
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol (2009) 5.55
Gold nanoparticles in delivery applications. Adv Drug Deliv Rev (2008) 4.81
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. Exp Cell Res (2005) 2.62
Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev (2007) 2.52
Endostatin's antiangiogenic signaling network. Mol Cell (2004) 1.95
Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol (2010) 1.84
Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun (2007) 1.69
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res (2007) 1.48
Control of tumour vascular permeability. Adv Drug Deliv Rev (1998) 1.41
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther (2008) 1.31
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2011) 1.22
Targeted therapies of cancer: angiogenesis inhibition seems not enough. Cancer Lett (2010) 1.12
Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J Pathol (2010) 1.06
Gold nanoparticles as carriers for efficient transmucosal insulin delivery. Langmuir (2006) 1.05
Calcium phosphate-based composite nanoparticles in bioimaging and therapeutic delivery applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.94
Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells. Mol Biol Rep (2011) 0.94
Genetic targeting of sprouting angiogenesis using Apln-CreER. Nat Commun (2015) 0.92
Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials (2014) 0.91
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer. Cancer Res (2014) 0.87
Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis. Cancer Lett (2015) 0.87
Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Mol Cancer Ther (2003) 0.85
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Sci Rep (2015) 0.85
Inhibition effects of gold nanoparticles on proliferation and migration in hepatic carcinoma-conditioned HUVECs. Bioorg Med Chem Lett (2013) 0.84
Cell and nanoparticle transport in tumour microvasculature: the role of size, shape and surface functionality of nanoparticles. Interface Focus (2016) 0.81
Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia. Sci Rep (2015) 0.80
Pericytes: a double-edged sword in cancer therapy. Future Oncol (2015) 0.80
Antibacterial efficacy of acridine derivatives conjugated with gold nanoparticles. Int J Pharm (2014) 0.79
Component-Specific Analysis of Plasma Protein Corona Formation on Gold Nanoparticles Using Multiplexed Surface Plasmon Resonance. Small (2015) 0.78
Gold nanoparticles inhibit VEGF165-induced migration and tube formation of endothelial cells via the Akt pathway. Biomed Res Int (2014) 0.93
Epirubicin-gold nanoparticles suppress hepatocellular carcinoma xenograft growth in nude mice. J Biomed Res (2015) 0.76